US › Healthcare

aTyr Pharma, Inc. (ATYR)

US · Healthcare · Biotechnology

$0.38-1.98%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-10.3M

EPS

$-0.11

EPS estimate

$-0.15

EPS came in at -0.11 against a street estimate of -0.15 — a beat of 26.7%.

Key statistics

Market cap

$42.4M

Forward P/E

0.0

P/B

0.92

Book value

$0.50

EPS (TTM)

$-0.60

52-week high

$1.37

52-week low

$0.40

50-day MA

$0.52

200-day MA

$0.69

Beta

0.53

Analyst view

Analysts rate aTyr Pharma, Inc. a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $2.86.

Shareholding

Insiders

2.45%

Institutions

39.84%

Largest institutional holders

Fund	Stake
FMR Inc	14.99%
Federated Hermes Inc	8.68%
BlackRock Inc	6.57%
UBS Group AG	3.94%
Vanguard Capital Management, LLC	3.89%
GSA Capital Partners LLP	3.52%
Geode Capital Management, LLC	2.43%
State Street Corp	1.79%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for aTyr Pharma, Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.